{"id":11187,"date":"2023-12-27T07:00:00","date_gmt":"2023-12-27T06:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-forlanger-vds-forordnande\/"},"modified":"2023-12-27T07:00:00","modified_gmt":"2023-12-27T06:00:00","slug":"irlab-forlanger-vds-forordnande","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/","title":{"rendered":"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande"},"content":{"rendered":"
\n

G\u00f6teborg, Sverige, 27 december 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att f\u00f6rordnandet f\u00f6r bolagets VD Gunnar Olsson har f\u00f6rl\u00e4ngts.<\/strong><\/p>\n<\/div>\n

\n

Styrelsen har kommit \u00f6verens med bolagets VD, Gunnar Olsson, att f\u00f6rl\u00e4nga hans f\u00f6rordnade. Avtalet har kort upps\u00e4gningstid och ger ingen r\u00e4tt till ers\u00e4ttning vid anst\u00e4llningens avslutande. En process f\u00f6r att ers\u00e4tta honom p\u00e5g\u00e5r.<\/p>\n

F\u00f6r mer information<\/strong>
Carola Lemne, styrelseordf\u00f6rande
E-mail: carola.lemne@irlab.se<\/a><\/p>\n

Om IRLAB<\/strong>
IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan hj\u00e4rnans signalsubstanser och CNS-st\u00f6rningar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 balans och fallfrekvens vid Parkinson. Dessutom utvecklar bolaget \u00e4ven de tre prekliniska programmen IRL942, IRL757 och IRL1117 mot Fas I-studier. Pipelinen drivs av IRLAB:s egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k www.irlab.se<\/a>.<\/p>\n<\/div>\n

\n

F\u00f6r mer information:<\/strong><\/p>\n

\n

Carola Lemne, styrelsens ordf\u00f6rande
Tel: +46 722 25 28 20
E-post: carola.lemne@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan hj\u00e4rnans signalsubstanser och CNS-st\u00f6rningar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 balans och fallfrekvens vid Parkinson. Dessutom utvecklar bolaget \u00e4ven de tre prekliniska programmen IRL942, IRL757 och IRL1117 mot Fas I-studier. Pipelinen drivs av IRLAB:s egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k\u00a0www.irlab.se<\/a>.<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, Sverige, 27 december 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att f\u00f6rordnandet f\u00f6r bolagets VD Gunnar Olsson har f\u00f6rl\u00e4ngts.<\/p>\n","protected":false},"template":"","class_list":["post-11187","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-staff_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, Sverige, 27 december 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att f\u00f6rordnandet f\u00f6r bolagets VD Gunnar Olsson har f\u00f6rl\u00e4ngts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/\",\"name\":\"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2023-12-27T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande - IRLAB","og_description":"G\u00f6teborg, Sverige, 27 december 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att f\u00f6rordnandet f\u00f6r bolagets VD Gunnar Olsson har f\u00f6rl\u00e4ngts.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/","name":"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2023-12-27T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-forlanger-vds-forordnande\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB f\u00f6rl\u00e4nger VD:s f\u00f6rordnande"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/11187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=11187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}